Validation of the BRCA1 antibody MS110 and the utility of BRCA1 as a patient selection biomarker in immunohistochemical analysis of breast and ovarian tumours

Virchows Archiv

Volumn 462, Issue 3, 2013, Pages 269-279

  Milner, Roy ^a   Wombwell, Helen ^a   Eckersley, Sonia ^a   Barnes, Donna ^a   Warwicker, Juli ^a   Van Dorp, Erica ^a   Dearden, Simon ^a   Hughes, Glen ^a   Harbron, Chris ^a   Wellings, Bob ^a   Hodgson, Darren ^a   Womack, Chris ^a   Gray, Neil ^a   Lau, Alan ^a   O'Connor, Mark J ^a   Marsden, Catherine ^a   Kvist, Alexander J ^a,b  

^a ASTRAZENECA   (United Kingdom)

^b not available   (United Kingdom)

Author keywords

Antibody validation; BRCA1; Breast cancer; MS110; Patient selection

Indexed keywords

BRCA1 PROTEIN; CANCER ANTIBODY; MS110 ANTIBODY; UNCLASSIFIED DRUG; BRCA1 PROTEIN, HUMAN; DIAGNOSTIC AGENT; MONOCLONAL ANTIBODY; TRANSCRIPTOME; TUMOR MARKER;

ANTIBODY SPECIFICITY; ARTICLE; BREAST TUMOR; CONTROLLED STUDY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN VITRO STUDY; OVARY TUMOR; PATIENT SELECTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; TRIPLE NEGATIVE BREAST CANCER; VALIDATION STUDY; WESTERN BLOTTING; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; METABOLISM;

ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; BRCA1 PROTEIN; BREAST NEOPLASMS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; OVARIAN NEOPLASMS; TRANSCRIPTOME; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84876092158     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1368-y     Document Type: Article

References (28)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66-71
2. Narod SA, Foulkes WD (2004) BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4:665-676
3. Gudmundsdottir K, Ashworth A (2006) The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25:5864-5874
4. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC (1990) Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250:1684-1689
5. Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, Isaacs C, Peshkin B, Buys S, Venne V, Rowley PT, Loader S, Offit K, Robson M, Hampel H, Brener D, Winer EP, Clark S, Weber B, Strong LC, Thomas A (1998) Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol 16:2417-2425
6. Bansal A, Critchfield GC, Frank TS, Reid JE, Thomas A, Deffenbaugh AM, Neuhausen SL (2000) The predictive value of BRCA1 and BRCA2 mutation testing. Genet Test 4:45-48
7. Anonymous (2011) StatBite lifetime risk of breast cancer subtypes by race. J Natl Cancer Inst 103:537
8. Vorrius TR, Snyder K, Pica-Mendez A, Tan C, Laterza O, Toniatti C, Carpenter C, Lee H, Tanaka W, Zhang Z (2002) Immunohistochemical detection of BRCA-1 and BRCA-2 expression in human breast and ovarian tumors. J Histotechnol 32:202-203
9. Perez-Valles A, Martorell-Cebollada M, Nogueira-Vazquez E, Garcia-Garcia JA, Fuster-Diana E (2001) The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. J Clin Pathol 54:476-480
10. Bordeaux J, Welsh A, Agarwal S, Killiam E, Baquero M, Hanna J, Anagnostou V, Rimm D (2010) Antibody validation. Biotechniques 48:197-209
11. Dantzer F, de La Rubia G, Menissier-De Murcia J, Hostomsky Z, de Murcia G, Schreiber V (2000) Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry 39:7559-7569
12. Ame JC, Spenlehauer C, de Murcia G (2004) The PARP superfamily. Bioessays 26:882-893
13. Manders EM, Stap J, Brakenhoff GJ, van Driel R, Aten JA (1992) Dynamics of three-dimensional replication patterns during the S-phase, analysed by double labelling of DNA and confocal microscopy. J Cell Sci 103(Pt 3):857-862
14. McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT, Seigler HF, McCarty KS Sr (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res (Suppl) 46:4244-4248
15. Lambie H, Miremadi A, Pinder SE, Bell JA, Wencyk P, Paish EC, Macmillan RD, Ellis IO (2003) Prognostic significance of BRCA1 expression in sporadic breast carcinomas. J Pathol 200:207-213
16. Lee WY, Jin YT, Chang TW, Lin PW, Su IJ (1999) Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. Histopathology 34:106-112
17. Sun X, Gong Y, Rao MS, Badve S (2002) Loss of BRCA1 expression in sporadic male breast carcinoma. Breast Cancer Res Treat 71:1-7
18. Yoshikawa K, Honda K, Inamoto T, Shinohara H, Yamauchi A, Suga K, Okuyama T, Shimada T, Kodama H, Noguchi S, Gazdar AF, Yamaoka Y, Takahashi R (1999) Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 5:1249-1261
19. Fraser JA, Reeves JR, Stanton PD, Black DM, Going JJ, Cooke TG, Bartlett JM (2003) A role for BRCA1 in sporadic breast cancer. Br J Cancer 88:1263-1270
20. Alamshah A, Springall R, Gillett CE, Solomon E, Morris JR (2008) Use of a BRCA1 peptide validates MS110 as a BRCA1-specific antibody in immunohistochemistry. Histopathology 53:117-120
21. Watson P, Townley AK, Koka P, Palmer KJ, Stephens DJ (2006) Sec16 defines endoplasmic reticulum exit sites and is required for secretory cargo export in mammalian cells. Traffic 7:1678-1687
22. Balczon R, Bao L, Zimmer WE (1994) PCM-1, A 228-kD centrosome autoantigen with a distinct cell cycle distribution. J Cell Biol 124:783-793
23. Chodosh LA (1998) Expression of BRCA1 and BRCA2 in normal and neoplastic cells. J Mammary Gland Biol Neoplasia 3:389-402
24. Favy DA, Lafarge S, Rio P, Vissac C, Bignon YJ, Bernard-Gallon D (2000) Real-time PCR quantification of full-length and exon 11 spliced BRCA1 transcripts in human breast cancer cell lines. Biochem Biophys Res Commun 274:73-78
25. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J (2004) BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13:2443-2449
26. Wenger CR, Clark GM (1998) S-phase fraction and breast cancer - a decade of experience. Breast Cancer Res Treat 51:255-265
27. McGarry TJ, Kirschner MW (1998) Geminin, an inhibitor of DNA replication, is degraded during mitosis. Cell 93:1043-1053
28. Gonzalez MA, Tachibana KE, Chin SF, Callagy G, Madine MA, Vowler SL, Pinder SE, Laskey RA, Coleman N (2004) Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression. J Pathol 204:121-130